Nycomed seeks bidders for potential $13B sale

Swiss drugmaker Nycomed has hired Goldman Sachs to scout for buyers up for a $13.5 billion deal. Options include licensing Nycomed's experimental lung-disease drug, an IPO, or an outright sale of the entire company. The drugmaker's large business in Eastern Europe and Russia could make it attractive to Big Pharmas looking to grow in emerging markets. Report | Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.